SGP — SpyGlass Pharma, Inc. Common Stock stock price, charts and financials

Latest market price

24.64

-0.67-2.66%

Overview Short InterestFilings

SGPQT50SpyGlass Pharma, Inc. Common Stock·NASDAQ

Overview Short InterestFilings

24.64-2.66%

Loading chart...

Signal & projected range

Earnings big miss — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AUPH-2.30%$15.48 MESO+4.92%$16.73 ZBIO-1.42%$31.97 GHRS-1.42%$29.84 TSHA-1.37%$6.47 STOK-1.63%$32.18 ABCL+33.62%$9.26 VRDN-3.11%$22.86

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	33.43M	Perf Week	12.34%

Market Cap	846.20M	Forward P/E	-	EPS next Y	-2.69	Insider Trans	-	Shs Float	13.95M	Perf Month	26.11%

Enterprise Value	608.90M	PEG	-	EPS next Q	-	Inst Own	127.23%	Short Float	3.38%	Perf Quarter	-0.32%

Income	-44.26M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	11.02	Perf Half Y	-

Sales	0.00	P/B	2.02	EPS next Y	-18.13%	ROA	-10.21%	Short Interest	1.13M	Perf YTD	5.46%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-123.53%	52W High	31.58 -21.98%	Perf Year	-

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-11.54%	52W Low	16.61 48.36%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	6.85% 7.48%	Perf 5Y	-

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-	Oper. Margin	0.00%	ATR (14)	1.55	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	38.00	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	70.61	Recom	-

Dividend Gr. 3/5Y	-	Current Ratio	38.00	EPS Q/Q	-	SMA20	16.81%	Beta	1.45	Target Price	62.00

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	-	SMA50	24.86%	Rel Volume	0.66	Prev Close	25.31

Employees	68	LT Debt/Eq	-0.02	Earnings	Jun 25	SMA200	9.44%	Avg Volume	109.57K	Price	24.64

IPO Date	Feb 06, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	-896.13% -	Net Debt/EBITDA	9.18	Volume	72,029	Change	-2.66%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Mar-03-26	Reiterated	Jefferies		$62

Latest News

Aug-06-26

Aug-06-2604:05PM

SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updatesglobenewswire.com

Jul-26-26

Jul-26-2602:02AM

Spyglass Pharma (NASDAQ:SGP) Shares Gap Up – Still a Buy?defenseworld.net

Jul-25-26

Jul-25-2604:43AM

Affinity Asset Advisors LLC Buys Shares of 250,000 Spyglass Pharma, Inc. $SGPdefenseworld.net

Company

SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.

Ownership

Total institutional ownership127.23%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)		FY 2025 12/31/2025
Total Revenue		0
Cost of Goods Sold Incl. D&A		1
Gross Profit		-1
Selling, General and Administrative Excl. Other		12
Research and Development		29
Other Operating Expense		0
Operating Income		-41
Interest Expense		0
Unusual Expense		—
Non-Operating Income (Expense)		2
Net Income Before Taxes		-40
Income Taxes		0
Consolidated Net Income		-40
Net Income From Continuing Operations		-40
Net Income		-40
EPS (Recurring)		-1.19
EPS (Basic, Before Extraordinaries)		-1.19
EPS (Diluted)		-1.19
EBITDA		-39
Other After Tax Adjustments		—
Stock Option Compensation Expense		—
Price To Earnings Ratio		—
Price To Sales Ratio		—
Gross Margin		—
Operating Margin		—
Net Margin		—
Shares Outstanding		33
Market Capitalization		—
Operating Lease Expense		—

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.